A company has been created to develop "novel technology" to help treat type 1 diabetes and potentially negate the need for insulin injections.
The company, called Islexa, has been launched by the Cell and Gene Therapy Catapult (CGT) and the U.K.'s University of Aberdeen.
According to a release from the University of Aberdeen, the company will look to develop technology which reprograms pancreatic tissue that has been donated, turning it into "fully functional islets."
"Islets are organoids that produce multiple hormones, including insulin, and donated islets are already effectively treating severe cases of type 1 diabetes," Kevin Docherty, a professor at the University of Aberdeen, said.
The university said that the technology could offer thousands more patients with type 1 diabetes the option of an "islet transplant", which provides patients with glucose control that is both effective and long term, negating the need for insulin administration.
"Having a hugely expanded supply of lab grown islets will enable us to significantly extend this established clinical treatment," Docherty added.